Q1 2026 Surge Confirms Skyrizi/Rinvoq Momentum, But Wait Thesis Unchanged

What happened

AbbVie's Q1 2026 results showed net revenue up 12.4% YoY, driven by strong immunology performance (Skyrizi +29%, Rinvoq +20%) and neuroscience (+24%), leading management to raise 2026 EPS guidance to $14.18, implying 42% YoY growth. However, the DeepValue Master Report maintains its WAIT rating, as the post-Humira transition thesis depends on sustained demand-led share capture over multiple quarters, not a single beat. The report highlights that Skyrizi and Rinvoq together represent ~42% of revenue and warns that Rinvoq's exclusivity extension to 2037 remains conditional on pediatric exclusivity. Aesthetics, a distant third pillar, continues to face structural headwinds. Investors should wait for at least two more quarters of evidence confirming that immunology growth is durable and not merely a timing artifact before committing.

Implication

The strong Q1 beat and raised guidance increase the probability of the base case scenario (55% probability, $235 implied value). However, the DeepValue report's WAIT rating remains prudent given the two-product concentration and conditional Rinvoq exclusivity. The near-term risk-reward still favors patience; investors should consider trimming above $245 and accumulating near $210 on any pullback.

Thesis delta

The strong Q1 results and raised guidance increase confidence in the base case (implied value $235) but do not yet validate the demand-driven narrative sufficiently to upgrade the rating. The WAIT rating persists pending confirmation of sustained immunology growth in the next two quarters and resolution of Rinvoq exclusivity conditions.